Neurotherapeutics Course
  • Home
  • About This Training Program
  • Important Information
  • Course Evaluation
  • Faculty
  • Schedule of Activities
  • Student Instructions
  • 2021 Course Lecture Videos

Course Lecture Videos
​
2018 Course Offering of Training in Neurotherapeutics Discovery and Development for Academic Scientists


Session 1: Target and Pathway Interrogation
James Inglese, PhD, National Center for Advancing Translational Sciences, NIH

Session 2: Biology Basics for Identifying Hits
William Janzen, BS, Epizyme, Inc.

Session 3: Moving from Hit to Lead to Clinical Candidate
James Barrow, PhD, Johns Hopkins School of Medicine

Session 4: Antibody-Based Therapies
Gai Ayalon, PhD, Genentech

Session 5: Assessing Unmet Needs and Advancing Early Stage Medical Innovations
in Multiple Domains to Attract Resources and Progress to Clinical Impact

Steven Schachter, MD, Harvard Medical School
Mike Dempsey (The Innovation Cycle in Defining Clinical Needs) and John Collins, PhD [Putting Together an Action Plan to Patient: The Healthcare Innovation Cycle Guidance and Impact and Tracking System (GAITS)], CIMIT, Massachusetts General Hospital 

Session 6: Intellectual Property
Jeffrey W. Childers, PhD, Michael Best & Friedrich LLP

​Session 7: Alternative Approaches to Lead Generation
Sam J. Enna, PhD, The University of Kansas

Session 8: ADME
Kennan Marsh, PhD, AbbVie

​Session 9: Preclinical Models of CNS Disease: Efficacy and Target Engagement
Matthew Kennedy, PhD, Merck

Session 10: Rigor in Translational Drug Discovery and Development
Shai Silberberg, PhD, NIH/NINDS

Session 11: Toxicology
Adaline Smith, PhD, DABT, Ironwood Pharmaceuticals

Session 12: IND Enabling Studies and Preparation of the IND
Edward Spack, PhD, Medared

Session 13: Formulation and Route of Administration
James Cloyd III, PharmD, University of Minnesota

Session 14: Gene-base Therapies
Michael G. Kaplitt, MD, PhD, Weill Cornell Medical College

Session 15: Rethinking How to Treat Neurodegenerative Disease
Lee L. Rubin, PhD, Harvard University

​Session 16: Funding Academic Drug Discovery Research
Charles L. Cywin, PhD, NIH/NINDS

Collaborator’s Logos